Silexion Therapeutics Corp., a clinical-stage biotechnology company, has announced promising results from a preclinical study showcasing the significant efficacy of their RNA interference therapy, SIL204, in human lung cancer cell lines. The study demonstrated dose-dependent inhibition in cells with KRAS G12D mutations, supporting SIL204's potential as a versatile therapeutic for lung cancer. The company is also conducting additional studies on a previously untested KRAS mutation, with results expected to be released in the near future. Silexion plans to initiate a Phase 2/3 clinical trial in the second quarter of 2026 to further investigate SIL204 for the treatment of KRAS-driven solid tumor cancers.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。